Learn More

A Novel Patented Combination Therapy for Cognitive Function, ADHD, and Narcolepsy

Modamane’s lead innovation is a UK-patented pharmaceutical composition that combines modafinil with Lion’s Mane (Hericium erinaceus) extract. This therapy is designed to enhance cognitive performance through a unique dual mechanism: dopaminergic wakefulness paired with neurotrophic support.

Protected under UK Patent with international protection pathways and family expansion available.

Our patent covers composition, method of use, manufacturing processes, and combination therapy claims, providing broad and defendable protection across several neurological and cognitive health applications.

Scientific Rationale

Modafinil

Modafinil is a well-established wakefulness-promoting agent used in narcolepsy, ADHD, shift-work sleep disorder, and cognitive performance enhancement.

It works primarily by inhibiting dopamine reuptake, improving alertness, focus, and executive functioning.


Lion’s Mane Extract (Hericium erinaceus)

Lion’s Mane contains neuroactive compounds (hericenones and erinacines) which stimulate nerve growth factor (NGF) synthesis.

NGF supports:

  • Neuronal growth

  • Synaptic plasticity

  • Neuroregeneration

  • Memory and cognitive resilience

These properties have been demonstrated in preclinical and early human studies.


Synergistic Mechanism

The patented therapy leverages two complementary biological pathways:

  • Modafinil → Enhances wakefulness, alertness, and attentional capacity

  • Lion’s Mane → Promotes neurotrophic activity and neuronal maintenance

  • Combined → A differentiated strategy for cognitive improvement, expanding modafinil’s utility while supporting long-term neuronal health

This dual-action approach is not available in any existing treatment and forms the basis of Modamane’s patent claims.

Therapeutic Applications

The patented formulation is applicable to several high-value clinical areas:

  • ADHD (enhanced attention and reduced hyperactivity)

  • Narcolepsy and excessive daytime sleepiness (improved wakefulness)

  • Cognitive impairment and mild memory decline

  • General cognitive enhancement

By combining symptomatic improvement with neurotrophic support, this therapy addresses both short-term performance and long-term cognitive health.


Patent Coverage

The Modamane patent provides strong protection through:

  • Pharmaceutical composition claims: modafinil + Lion’s Mane extract

  • Defined ratio ranges ensuring synergistic effect

  • Manufacturing process claims, including extraction and formulation

  • Method-of-use claims for ADHD, narcolepsy, and cognitive enhancement

  • Combination therapy claims for simultaneous or sequential administration

This constitutes a robust and defensible IP position suitable for clinical development and commercial licensing.


Development & Partnership Opportunities

Modamane is seeking collaborations with:

  • Pharmaceutical manufacturers

  • Biotechnology companies

  • Digital therapeutics platforms

  • Clinical research organisations

    Opportunities include:

    • Full or partial licensing

    • Co-development agreements

    • Territory-exclusive partnerships

    • Clinical development alliances


    Our objective is to bring this patented combination therapy into clinical evaluation and unlock its therapeutic potential across multiple neurological indications.





Contact Business Development